Transport of patients in cardiogenic shock with mobile femoral-femoral cardiopulmonary bypass

Assistance circulatoire extracorporelle percutanée dans les défaillances hémodynamiques aiguës graves : Expérience monocentrique chez 100 patients consécutifs

“…Ces 20 patients sont tous survivants au suivi moyen de 16,8 ± 9,7 mois (médiane 17,6 mois, de 57 jours à 32 mois) ( Figure 2 Intoxication médicamenteuse † 6 (6) 6 (9) - (12,13).…”

Assist devices for circulatory support in therapy-refractory acute heart failure

“…The same group used an extracorporeal rotary pump, the MedosDeltaStream DP1 (Medos Medizintechnik AG, Stolberg, FR Germany) in two patients as a pediatric ECMO, which features a diagonal flow impeller, and can be used for both continuous and pulsatile output [83]. Out-of-hospital extracorporeal circulatory support, ECC or ECMO is not a new concept [84,85], but the first animal studies are now reported and present the successful use of a portable, modular, rapidly available 'Plug-and-Play' MCAD as bridge to therapy, the Lifebridge (Lifebridge Medizintechnik AG, Ampfing, FR Germany), which may serve a role beyond conventional cardiology and/or cardiovascular surgery [12,86]. Possible scenarios for percutaneous MCADs as therapy of refractory acute heart failure or arrest are listed below.…”